In this video, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, briefly discusses the role of whole exome sequencing in acute myeloid leukemia (AML), and further explains how the European LeukemiaNet (ELN) risk classification is becoming increasingly based on molecular genetics as more clinically informative mutations are identified. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.